
Keywords: Aβ; amyloid beta; AD; Alzheimer disease; ADAS-cog; Alzheimer's disease assessment scale-cognitive; AGEs; advanced glycation end products; ARIC; atherosclerosis risk in communities; CLOX-1; clock-drawing executive test; CVR; cerebrovascular responsivene